EGFR and non-small cell lung carcinoma: Gefitinib, erlotinib and icotinib, as the first-generation EGFR tyrosine kinase inhibitors (TKIs), greatly improve the prognosis of NSCLC patients with EGFR gene mutations (Ke and Wu, 2016; Goss et al., 2016; Lee, 2017).